Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT02790034 Terminated - Rett Syndrome Clinical Trials

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

STARS
Start date: October 26, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the safety, tolerability and efficacy of Sarizotan in reducing respiratory abnormalities in Rett Syndrome in an initial double blind 24 week period followed by an open label treatment phase of up to 168 weeks (the latter for patients with no safety and tolerability issues).

NCT ID: NCT02789917 Completed - Clinical trials for Coronary Artery Disease

APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF

APPROACH
Start date: June 2016
Phase: Phase 4
Study type: Interventional

It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and clopidogrel with respect to avoiding bleeding events in patients with atrial fibrillation undergoing percutaneous coronary intervention in the setting of an acute coronary syndrome.

NCT ID: NCT02789748 Completed - Clinical trials for Obstructive Sleep Apnea Syndrome

PErsonalized and Adaptive Kinesthetic stImulation Therapy, Based on Cardio-respiratory Holter moNitoring, for Sleep Apnea syndrOmes

EKINOx
Start date: June 1, 2016
Phase: N/A
Study type: Interventional

This study aims at quantifying the performance of kinesthetic stimulation to reduce the burden of obstructive sleep apneas and hypopneas.

NCT ID: NCT02789696 Completed - Clinical trials for Sleep Apnea Syndrome

Prevalence of Acromegaly in a Diagnostic Consultation for Sleep Apnea Syndrome

ACROSAS
Start date: November 2013
Phase: N/A
Study type: Interventional

Prevalence of sleep apnea syndrome in patients with acromegaly is about 70%. It seems that comorbidities of arterial hypertension or type 2 diabetes are more severe in patients with acromegaly and sleep apnea syndrome. Besides sleep apnea syndrome associated to acromegaly gives rise to few symptoms, that explains it is under diagnosed. The mechanisms of the association are based on maxillofacial modifications linked to acromegaly, a thickening of soft tissues with deposits of glyco-aminoglycanes but probably also because of the associated obesity, of the potential existence of a goiter and a muscular dystrophy of the dilatative muscles of the pharynx. At present, no study clearly documented prevalence of acromegaly in a diagnostic consultation for sleep apnea syndrome.

NCT ID: NCT02789488 Completed - Clinical trials for Poly Cystic Ovary Syndrome

Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome

Start date: September 2013
Phase: Phase 4
Study type: Interventional

Poly cystic ovary syndrome (PCOS) is a disease which is prevalent in women of reproductive age facing obesity along with increased risk of type-2 diabetes and high cholesterol levels. The genetically determined cause of the PCOS includes disturbed levels of insulin and androgens. Standardized fenugreek seed extract (Furocyst) contains compounds such as saponins & flavonoids which act on the insulin and indirectly helps to regulate the androgen levels in the body.

NCT ID: NCT02789150 Completed - Clinical trials for Hepatorenal Syndrome

Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg

Start date: January 2015
Phase: Early Phase 1
Study type: Interventional

Comparing renal outcomes based on a Mean Arterail Pressure (MAP) of 65-7085mmhg versus a MAP of greater than or equal to 85mmhg

NCT ID: NCT02788552 Completed - Clinical trials for Wernicke-Korsakoff Syndrome

Optimum Thiamine Intervention (OpTIn) Trial

OpTIn
Start date: September 2014
Phase: Phase 4
Study type: Interventional

Wernicke-Korsakoff syndrome (WKS), once thought to be a rare condition, is now known to be common in people with nutritional deficiencies or alcohol dependence. The primary cause of WKS is thiamine deficiency, and more than 90% of cases are reported in alcohol dependent patients because alcohol dependence predisposes to severe nutritional deficiency. WKS may lead to significant, long-term brain dysfunction with severe effects on work, personal and social function. Whilst effective treatment may greatly reduce severe disability and the human and social costs of this illness, almost no evidence exists on optimal dosing regimens. This project proposes to develop quality evidence for effective treatment of WKS in an Aboriginal setting.

NCT ID: NCT02788071 Completed - Clinical trials for Irritable Bowel Syndrome

Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome

Start date: October 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to investigate if fecal microbiota transplantation (FMT) will result in improvement in clinical outcome in patients with irritable bowel syndrome (IBS).

NCT ID: NCT02787941 Recruiting - Clinical trials for Acute Coronary Syndrome

Pharmacist-led Intervention to Enhance Medication Adherence in Post-acute Coronary Syndrome Patients in Vietnam

Start date: November 2015
Phase: N/A
Study type: Interventional

Adherence to treatment in post-acute coronary syndrome patients has been found to be poor in several studies. Pharmacists play a significant role in enhancing medication adherence and reducing rates of mortality and re-admission to hospital by performing medication reconciliation and tailoring, and patient education. The purpose of this study is to determine the effect of pharmacist-delivered multifaceted intervention on medication adherence and clinical outcomes of post-acute coronary syndrome patients. The study will be designed as a randomised controlled trial with blinded outcome assessors. The population includes patients who survive during hospitalisation with discharge diagnosis of acute coronary syndrome. Pharmacist-delivered multifaceted intervention consists of two counselling sessions within 1 week before and after hospital discharge including medication reconciliation and tailoring, and support with pill organiser and drug information leaflet. Primary outcome measure is the proportion of patients adherent to medication at 1 month after discharge. Secondary outcome measures are the proportions of patients (1) adherent to medication at 3 months after discharge, (2) readmitted to hospital and (3) dying within 3 months after discharge. The investigators also measure (4) the change in quality of life and (5) beliefs about medicines from baseline at 3 months.

NCT ID: NCT02787720 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Rehabilitation Techniques on Survivors of Acute Respiratory Distress Syndrome

Start date: December 2009
Phase: N/A
Study type: Interventional

A randomized controlled blinded study in patients treated for Acute Respiratory Distress Syndrome (ARDS) in the mixed medical-surgical intensive care units (ICU) of four academic teaching hospitals in Tehran, Iran were conducted to examine the effects of Varied Rehabilitation Techniques on Survivors of ARDS patients. Patients were randomized in the emergency department at the time of ICU admission to one of four groups labeled groups 1, 2, 3 and 4, respectively.